1. Home
  2. DFNS vs BOLD Comparison

DFNS vs BOLD Comparison

Compare DFNS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFNS

T3 Defense Inc. Common Stock

N/A

Current Price

$0.60

Market Cap

27.2M

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.15

Market Cap

25.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFNS
BOLD
Founded
2013
2018
Country
United States
United States
Employees
15
N/A
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
25.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
DFNS
BOLD
Price
$0.60
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
1.2M
61.2K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.96
52 Week High
$2.68
$1.78

Technical Indicators

Market Signals
Indicator
DFNS
BOLD
Relative Strength Index (RSI) 19.61 42.47
Support Level N/A $0.99
Resistance Level $2.44 $1.20
Average True Range (ATR) 0.12 0.04
MACD -0.02 -0.00
Stochastic Oscillator 17.99 16.67

Price Performance

Historical Comparison
DFNS
BOLD

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: